Aadi Bioscience (FRA:3350) EV-to-Revenue : -1.82 (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aadi Bioscience's enterprise value is €-40.14 Mil. Aadi Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €22.03 Mil. Therefore, Aadi Bioscience's EV-to-Revenue for today is -1.82.

The historical rank and industry rank for Aadi Bioscience's EV-to-Revenue or its related term are showing as below:

FRA:3350' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.79 Med: 6 Max: 363.75
Current: -1.83

During the past 4 years, the highest EV-to-Revenue of Aadi Bioscience was 363.75. The lowest was -2.79. And the median was 6.00.

FRA:3350's EV-to-Revenue is ranked better than
95.08% of 1037 companies
in the Biotechnology industry
Industry Median: 7.83 vs FRA:3350: -1.83

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-07), Aadi Bioscience's stock price is €1.58. Aadi Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.82. Therefore, Aadi Bioscience's PS Ratio for today is 1.93.

Aadi Bioscience EV-to-Revenue Historical Data

The historical data trend for Aadi Bioscience's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience EV-to-Revenue Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

356.22

9.37

-2.38

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial										1.45	1.59	0.03	-2.38	-1.24

Competitive Comparison of Aadi Bioscience's EV-to-Revenue

For the Biotechnology subindustry, Aadi Bioscience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's EV-to-Revenue falls into.

Aadi Bioscience EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aadi Bioscience's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-40.139	/	22.034
	=	-1.82

Aadi Bioscience's current Enterprise Value is €-40.14 Mil.
Aadi Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.03 Mil.

Aadi Bioscience (FRA:3350) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aadi Bioscience's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.58	/	0.818
	=	1.93

Aadi Bioscience's share price for today is €1.58.
Aadi Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.82.

Aadi Bioscience EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines